Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-09-20 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the expanded approval of Dupixent for treating eosinophilic esophagitis (EoE) in children in the EU. This type of announcement, detailing clinical trial results and regulatory milestones in a public, non-periodic format, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a key business/regulatory event (drug approval progress) rather than a comprehensive financial report (10-K, IR) or a transcript (CT), it fits best under the 'Earnings Release' category, which often encompasses major operational and regulatory news releases, or 'RNS' as a general regulatory announcement. Given the focus on a specific regulatory milestone and clinical data summary, ER is often used for such major news, but RNS is the designated fallback for general regulatory announcements. Since this is a press release announcing a regulatory development, and it is not a comprehensive financial report, RNS (Regulatory Filings) is the most appropriate general category, although ER is also plausible if the company typically bundles such news there. Given the options, RNS covers general regulatory news releases well. However, many companies issue press releases for major clinical/regulatory updates alongside or instead of a formal ER. Since this is a press release announcing a regulatory event, and it is not a comprehensive financial report, RNS is the safest classification as a general regulatory announcement.
2024-09-20 English
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Earnings Release Classification · 100% confidence The document is explicitly titled '# **Press Release**' and details positive clinical trial results (HERCULES, GEMINI 1 & 2) for a drug (tolebrutinib), including statistical data, adverse event tables, and future regulatory submission timelines ('Global regulatory submissions will begin in H2 2024'). This format—a formal announcement of significant, time-sensitive business/scientific news—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing key results rather than a comprehensive periodic financial report (like 10-K or IR), and it focuses on operational/scientific milestones rather than just financial figures, it fits best as an Earnings Release (ER) if it were quarterly/periodical results, or RNS if it's a general announcement. Given the context of presenting clinical trial data, which often accompanies or precedes financial reporting periods, and the structure being a 'Press Release' announcing key findings, ER is a strong candidate if this is tied to a reporting cycle. However, since the content is primarily clinical trial data and future submission plans, and not a summary of quarterly financials, it is more accurately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. Since it is a press release announcing data presented at a conference (ECTRIMS), and it doesn't fit the specific definitions of ER (which usually focuses on financial performance summary), AR, or IP (which is usually a presentation deck), RNS serves as the most appropriate general regulatory announcement category for significant, non-standardized corporate news. Q3 2024
2024-09-20 English
CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques sec
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and details positive clinical trial results (Phase III HERCULES study) for a drug called tolebrutinib concerning Multiple Sclerosis (MS). It includes key efficacy and safety data, quotes from researchers and management, and mentions future regulatory submission plans ("Le dépôt de soumissions réglementaires débutera au deuxième semestre de 2024 à l'échelle mondiale"). This format—a formal announcement of significant scientific/business news, often released to the public and media simultaneously with or just before a regulatory filing—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing clinical trial results and future regulatory steps, and not a full financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific scientific/regulatory update. Given the content is a major scientific/pipeline update rather than standard quarterly financial performance highlights, and it explicitly states regulatory submissions are coming, it functions as a significant, non-standard regulatory announcement. However, in many databases, major clinical trial result announcements that precede formal filings are often categorized under the general Regulatory Filings (RNS) or sometimes as an Earnings Release (ER) if the company treats pipeline updates as key performance indicators. Since the document is a press release announcing clinical data and future regulatory steps, and it is not a short announcement pointing to an attached report (ruling out RPA), RNS is the most appropriate general category for significant, non-standard regulatory/pipeline news. I will classify it as RNS as it is a broad regulatory announcement about clinical data and future filings.
2024-09-20 French
Sanofi: Information concerning the total number of voting rights and shares - August 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns 'Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce' and article 223-16 of the AMF Regulation. It provides a table detailing the total number of issued shares and voting rights as of a specific date (August 31, 2024). This content directly relates to official announcements regarding voting rights and share structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a mandatory disclosure of the current voting rights structure.
2024-09-16 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the total number of shares and voting rights as of August 31, 2024, referencing French commercial code and AMF regulations. This specific disclosure relates to the total voting rights and share capital, which is a mandatory regulatory filing in France, often related to capital structure or shareholder information. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a specific regulatory disclosure concerning capital structure or voting rights. Given the options, this type of mandatory disclosure about the total number of shares and voting rights, which is a specific regulatory requirement, fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Total Voting Rights Disclosure'. It is a formal regulatory update, not a presentation (IP) or a management discussion (MDA).
2024-09-16 French
6-K
Regulatory Filings
2024-09-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.